50
Participants
Start Date
September 17, 2020
Primary Completion Date
October 1, 2027
Study Completion Date
October 1, 2030
Upfront autologous HSCT
"HSCT comprises the following consecutive steps:~1. Mobilisation~ * Infusions of CYC 2g/m2 on 1 day.~ * Hyperhydration, alkalinisation of urine and mesna to prevent haemorrhagic cystitis.~ * Filgrastim (G-CSF) 5-10 μg/kg/day subcutaneously for 5 days (or more when necessary).~2. Leukapheresis Prompt start of leukapheresis is required at a CD34+ cell count of ≥10-20/μL. Goal: at least 2 x 10\^6 CD34+ cells per kilogram body weight.~3. Conditioning~ * CYC 50 mg/kg/day intravenously for 4 consecutive days (total 200 mg/kg)~ * Rabbit Antithymocyte Globulin (rbATG), a total dose of 7.5 mg/kg i.v., from Genzyme.~ Hyperhydration, alkalinisation of the urine and mesna will be given to prevent haemorrhagic cystitis.~ I.v. methylprednisolone 2 mg/kg will be administered on the days ATG, to improve tolerability of the ATG.~4. Peripheral stem cell infusion The number of CD34+ cells to be reinfused should be ≥ 2.0 x 10\^6/kg."
NOT_YET_RECRUITING
Gaetano Pini-CTO, Milan
RECRUITING
Ospedale San Raffaele, Milan
NOT_YET_RECRUITING
University Hospital Rome, Roma
RECRUITING
Amsterdam Rheumatology Centre, Amsterdam
RECRUITING
University Medical Centre Leiden, Leiden
RECRUITING
Radboudumc Nijmegen, Nijmegen
RECRUITING
University Medical Centre Utrecht, Utrecht
RECRUITING
Skåne University Hospital Lund, Lund
RECRUITING
Karolinska Institute/Karolinska University Hospital Solna, Stockholm
NOT_YET_RECRUITING
University Hospital Basel, Basel
NOT_YET_RECRUITING
Inselspital, Universitätsspital Bern, Bern
NOT_YET_RECRUITING
Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield
Collaborators (2)
ZonMw: The Netherlands Organisation for Health Research and Development
OTHER
Boehringer Ingelheim
INDUSTRY
Miltenyi Biotec, Inc.
INDUSTRY
UMC Utrecht
OTHER